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MS ID#: Endocrinology en.2017-00111 Response to Editors’ and Reviewers’ Comments. 
 
We thank the editors and reviewers for their detailed and supportive comments. We are delighted to learn 
from the editor’s letter that this manuscript “…should be acceptable for publication in Endocrinology 
pending minor revisions as suggested by the reviewers…” and that “…both reviewers liked this study…” 
Moreover, we are grateful for the reviewers’ supportive comments, and note that: reviewer #1 states that 
“…These findings are both biologically and clinically significant…”; and reviewer #2 states that “…The 
studies were methodically and rigorously conducted and the manuscript easy to read and well-written…” 
 
We have addressed the editors’ and reviewers’ comments, undertaken additional experiments and provided 
the information that was requested. 
 
en.2017-00111 - Editors’ Comments 
 
Raj, both reviewers liked this study. However, each had a number of concerns. Chief among them is the 
limited number of animals used for a number of the studies, which made it hard to form firm conclusions. I 
recommend that these numbers be increased. Moreover, the gender differences need to be addressed. I 
am rating this as a minor revision, but in some cases new data will need to be provided. 
 
We thank the editor for these helpful comments, and over the past 8 weeks we have utilized additional mice 
for the in vivo glucose tolerance testing, as well for the ex vivo electrophysiological and hormone secretion 
experiments to ensure that all data has been generated from a minimum of n=4 biological replicates. We 
have also made clear in the Results section that there were differences in plasma insulin and glucagon 
concentrations between male and female mice, and also highlighted the differing responses of male and 
female mice to treatment with the ronacaleret drug compound. Moreover, in response to a comment from 
reviewer #1 about the effect of glucose on calcium-sensing receptor (CaSR) activation, we have undertaken 
additional cellular studies to characterize the effect of alterations in glucose concentrations on CaSR 
signaling responses. This additional data has necessitated the inclusion of Dr Caroline Gorvin as a co-author, 
and all of the authors are agreed to the inclusion of this individual in the authorship, as well as her position 
in the authorship order. 
 
en.2017-00111 - Reviewers’ Comments 
 
Reviewer #1: Babinsky et al took in vivo and in vitro approaches to investigate the impact of an activating 
CaSR mutation (Leu723Gln, also named Nuf mutation) on energy metabolism and pancreatic α- and β-cell 
functions. The animal studies which were well performed showed the development of hypocalcemia, 
hypoinsulinemia, and impaired glucose tolerance and secretion of insulin and glucagon in +/Nuf or Nuf/Nuf 
mice carrying, respectively, heterozygous or homozygous germ-line CaSR mutation. These defects were 
partly rectified by oral administrations of Ronacaleret, an allosteric CaSR antagonist, supporting a role for 
the CaSR in mediating energy metabolism. These findings are both biologically and clinically significant. 
 
We are grateful to the Reviewer for the supportive comments that the animal studies “…were well 
performed …” “…supporting a role for the CaSR in mediating energy metabolism…” and that “…These 
findings are both biologically and clinically significant…” 
 
The authors then cultured pancreatic islets from wt and Nuf/Nuf mice and performed ex vivo insulin and 
glucagon secretion assays (Figure 6) to elucidate cell-autonomous actions of Wt vs Nuf CaSRs.  Their results 
convincingly showed no significant difference in the ability of raising glucose concentration (from 1 to 6 
mM) to induce insulin secretion between two genotypes (Figure 6A,B), but a defect in the glucose-induced 
suppression of glucagon secretion (Figure 6C,D), supporting a cell-autonomous action of CaSR in α-cells.   
 
We thank the Reviewer for these helpful and supportive comments. 
 
Point-by Point Rebuttal
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In separate experiments, the authors further tested the effects of changing [Ca2+]o (from 0.8 to 1.6 mM) 
on the glucose-induced insulin (Figure 6E) and glucagon (Figure 6F) secretion. However, the sample sizes 
for some data points were small (N =3 or 4) and had large variations, so the results are difficult to interpret 
for a clear conclusion.   
  
We are grateful to the reviewer about this important point regarding the sample sizes in Figures 6E-F. Over 
the past 8 weeks, we have undertaken additional studies using cultured pancreatic islets to increase the 
sample sizes. In particular, we used an additional N=3 CasrNuf/Nuf mice to increase the batches of Nuf/Nuf 
islets previously studied from N=3 to N=5-8 batches of islets (highlighted in yellow in figure below), and this 
increase in the sample size has not affected the significance of our findings. We have amended Figures 6E-F 
with this additional data (please see below). 
 
 
 
Moreover, we have inserted the following text in the figure 6 legend regarding the sample sizes: “…The 
sample size (N) represents batches of size-matched islets, which were pooled from 3-6 Casr+/+ mice and 6 
CasrNuf/Nuf mice…” 
 
Furthermore, there was no clear rational for choosing 0.8 and 1.6 mM Ca, over the ones in the range (2-5 
mM) in which wt and Nuf CaSRs display different signaling capacities (Figure 2). These pitfalls prevent a 
clear conclusion on a role of CaSR in rendering β-cells ablility to sense and respond to changes in [Ca2+]o. 
 
We thank the reviewer for this comment, and would like to explain that for these ex vivo studies, we used 
0.8 mM calcium to simulate the prevailing circulating ionized calcium concentrations in Casr Nuf/Nuf mice, as 
we have previously reported Casr Nuf/Nuf mice to have albumin-adjusted calcium concentrations of 1.5-1.6 
mM, which is equivalent to ionized calcium concentrations of 0.75-0.80 mM (Hough et al PNAS 2004, 
Hannan et al Endocrinology 2015). We also used 1.6 mM calcium, as this has been reported to represent a 
physiological calcium concentration, which is used in ex vivo studies involving Krebs-Ringer Buffer solutions 
(MacConaill J Pharmacol Methods 1985), it coincidentally represents a ~2-fold increase in the prevailing 
concentrations in Casr Nuf/Nuf mice. To clarify this, we have amended the Results text, as follows: “…size-
matched islets were isolated from Casr+/+ and CasrNuf/Nuf mice, and exposed to low (1 mM), physiological (6 
mM) or high (20 mM) glucose concentrations in the presence of 1.6 mM [Ca2+]o, which represents a 
physiological [Ca2+]o (36)…” and “…To investigate whether the reduced plasma insulin concentrations of Nuf 
mice may have been a consequence of their hypocalcemia, insulin secretion from isolated islets was 
measured following exposure to 0.8 mM [Ca2+]o, which is similar to the plasma calcium concentrations 
observed in CasrNuf/Nuf mice (15,16)…” Moreover, we have inserted the following text in the Methods: “…A 
Krebs-Ringer buffer containing 0.8 mM CaCl2 was used to evaluate the effect of lowering the [Ca2+]o on islet 
hormone secretion…” and inserted an additional reference regarding the use of physiological (1.6 mM) 
calcium concentrations in Ringer solutions: “…36. MacConaill M. Calcium precipitation from mammalian 
physiological salines (Ringer solutions) and the preparation of high [Ca] media. J Pharmacol Methods 1985; 
14:147-155…” 
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The authors compared pancreatic islets sizes and numbers by standard histology (Figure 5A), which 
convincingly showed fewer and smaller islets in +/Nuf and Nuf/Nuf pancreata.  
 
We thank the Reviewer for this supportive comment. 
 
They further performed immunohistochemistry to quantify α- and β-cell numbers in islets of wt and Nuf 
mice and concluded that there were modestly reduced β-cell numbers (Figure 5E,F), but increased α-cell 
(Figure 5E,G) numbers in the Nuf mutant mice. However, the methods used to quantify these cell numbers 
and normalize the data (Figure 5F,G) were not described 
 
We are grateful to the reviewer for this comment, and have inserted the following text in the Methods to 
clarify how the cell numbers were quantified and normalized: “…The numbers of α- and β-cells within 
individual islets were quantified using the cell-based analysis profile of the TissueQuest software (27), and 
normalized to the total islet area, and reported as percentage of the mean numbers of Casr+/+ α- and β-cells, 
respectively…” 
 
The authors intended to measure cell proliferation rate by Ki-67 staining. However, it's to be reminded that 
Ki-67 only indicates the status of cell proliferation, but not the speed of proliferation.  To assess cell 
proliferation rates, BrdU incorporation over a given period of time is a better approach.   
 
We agree with the reviewer that Ki-67 staining indicates the status of cell proliferation, but not the 
proliferation rate, and have amended the y-axis title of the Ki67 graphs (panels I-J in Figure 5), so that this 
reads as “…% of proliferating…cells…” rather than “…% proliferation rate…”. Moreover, we have modified 
the Results text, as follows: “…The percentage of proliferating insulin-positive β-cells in CasrNuf/Nuf mice was 
found to be significantly decreased (p < 0.05), whereas the percentage of proliferating insulin-negative cells 
(which are predominantly α-cells) was significantly increased when compared to respective Casr+/+ islets 
(Figure 5I-J)…” Furthermore, in the Discussion, we have highlighted the advantages of using BrdU 
incorporation to assess proliferation, as follows: “…-cell proliferation was measured using the Ki67 marker, 
which shows proliferation over a limited timeframe, and long-term continuous labeling with the thymidine 
analog 5-bromo-2-deoxyuridine (BrdU) is required to provide a more accurate assessment of proliferation 
(43)…” The inclusion of this text in the Discussion has necessitated the insertion of an additional reference: 
“…43. Walls GV, Reed AA, Jeyabalan J, Javid M, Hill NR, Harding B, Thakker RV. Proliferation rates of 
multiple endocrine neoplasia type 1 (MEN1)-associated tumors. Endocrinology 2012; 153:5167-5179...“ 
 
The authors should also consider the possibility that cell death may contribute to recued islet number and 
size in the Nuf mice. 
 
We thank the reviewer for this important point, and have modified the Discussion text to emphasize this, as 
follows: “…alterations in cellular proliferation can substantially impact on adult -cell mass and insulin 
secretory capacity (42). Furthermore, the CaSR may have influenced -cell apoptosis, which has been shown 
to contribute to the reduced islet mass in humans with type 2 diabetes (44)…” We have also inserted the 
following reference: “…44. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit 
and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-110...” 
 
The authors performed whole-cell recordings to compare electrophysiological activities in α- and β-cells of 
Wt vs Nuf mice and their responses to different glucose and Ca concentrations. Their data suggest that 
impaired electrophysiological responses to glucose and tolbutamide (KATP channel blockers) may underlie 
the aberrant glucagon secretion in α-cells of Nuf mice. Again, the rationale for choosing 0.75 and 1.5 mM 
Ca in these experiments was not provided.  
 
We are grateful to the reviewer for this comment, and would like to explain that 1.5 mM represents a 
standard physiological calcium concentration used in previously reported electrophysiological studies 
involving intact islets (e.g. Shigeto et al. J Clin Invest 2016). We also used 0.75 mM calcium to simulate the 
circulating ionized calcium concentrations of 0.75-0.80 mM in Casr Nuf/Nuf mice (Hough et al PNAS 2004, 
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Hannan et al Endocrinology 2015); moreover we choose 0.75 mM rather than 0.80 mM as it represents a 
50%, as opposed to 46.7% reduction, and allows measurements following a 2-fold change in calcium, and is 
consistent with the 2-fold change in the secretion studies of Figures 6E and 6F. We have clarified the use of 
these calcium concentrations by modifying the Methods text, as follows: “…Islets were immobilised using a 
wide-bore glass suction pipette (24) and perfused with modified Krebs-Ringer solution (140 mM NaCl, 3.6 
mM KCl, 1.5 mM CaCl2, 0.5 mM MgSO4, 10 mM HEPES, 0.5 mM NaH2PO4 and NaHCO3 at pH 7.4 with NaOH, 
and glucose as indicated), as reported (25). A Krebs-Ringer solution containing 0.75 mM CaCl2 was used to 
evaluate the effect of lowering the [Ca2+]o on islet electrical activity…” and by inserting the following text in 
the Results: “…The electrophysiological experiments were undertaken at 1.5 mM [Ca2+]o, as described (25), 
and the effect of lowering the [Ca2+]o on β-cell electrical activity was evaluated at 0.75 mM [Ca2+]o, which is 
in keeping with the plasma calcium concentrations of CasrNuf/Nuf mice (15,16)…” 
 
In addition, voltage-clamping protocols for the experiments described in Figure 8 were not clearly 
described.   
 
We apologize to the reviewer for not clearly describing this, and have inserted the following text in the 
Methods: “…The conductance of the β-cell ATP-sensitive K+ (KATP) channel within intact islets was measured 
using the perforated patch clamping technique following exposure to different glucose concentrations or to 
tolbutamide (24). During the KATP channel conductance studies, β-cells were held at -70 mV, and K+ currents 
were evoked by exposing the cells to alternating 50 ms pulses of -60 or -80 mV (25)…” 
 
It is also unclear how many mice and batches of islets were used in these electrophysiological 
studies.  Considering their large variations, some data points with N= 3 or 4 seem to be statistically 
underpowered, delegitimizing the authors' interpretation and conclusion.   
 
We are grateful to the reviewer about this important point, and during the revision of this manuscript we 
undertook additional electrophysiological experiments to increase the sample sizes. We have updated 
figures 7 and 8 with this additional data (please see updated figures on pages 11 & 12 of this response 
letter), and the increase in the sample sizes has not affected the significance of our findings. Moreover, we 
have inserted the following text in the legends to figures 7-9 to clarify what the sample sizes represent: 
 
Figure 7 legend: “…The sample size (N) represents individual β-cell recordings obtained from intact islets of 
6 Casr+/+ mice and 4 CasrNuf/Nuf mice…” 
 
Figure 8 legend: “…The sample size (N) represents individual β-cell recordings obtained from intact islets of 
5 Casr+/+ mice and 5 CasrNuf/Nuf mice…” 
 
Figure 9 legend: “…The sample size (N) represents individual α-cell recordings obtained from intact islets of 
5 Casr+/+ mice and 7 CasrNuf/Nuf mice…” 
 
Other comments: 
Materials and Methods: 
- Page 8, 2nd paragraph: In islet insulin and glucagon secretion assays, the [Ca] bathing the islets 
before they were switched to 0.8 and 1.6 mM Ca was not stated. 
 
We thank the Reviewer for this comment and to clarify the calcium concentration that the islets were 
incubated in, we have modified the Methods text, as follows: “…Batches of 13 size-matched islets were 
incubated for 1 hour at 37°C in 0.3 ml of modiﬁed Krebs-Ringer buffer containing 2mg/ml BSA, 1.6 mM CaCl2 
and 3mM glucose, followed by a 1 hour incubation in 0.3 ml of the same Krebs-Ringer buffer supplemented 
with 1, 6 or 20 mM glucose, as described (21)…” 
 
- Sample sizes in some data points in Figures 3, 4, 6, and 8 and supplementary Figure 3 are too small 
and statistically underpowered. 
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We are grateful to the reviewer for this comment, and over the past 8 weeks we have utilized additional 
mice for the in vivo glucose tolerance testing, as well for the ex vivo electrophysiological and hormone 
secretion experiments to ensure that all data has been generated from a minimum of n=4 biological 
replicates. We have incorporated this additional data into Figures 3, 4, 6, 7 and 8; and also into 
supplementary Figure 1 and supplementary Figure 3 (which is now relabelled as supplementary Figure 4). 
Increasing the sample sizes has not altered the significance of our findings (please see updated figures on 
pages 8-14 of this response letter). 
Results: 
- Figure 2B and 2C: Have the authors tested whether glucose allosterically modulates CaSR activation 
in their assays as previously reported (www.jbc.org/content/291/44/23126) and whether Nuf mutant has 
different responses to glucose. 
 
We thank the reviewer, and to address this important comment we have generated HEK293 cells stably 
expressing the WT and mutant Nuf CaSRs, and evaluated whether glucose may allosterically modulate CaSR 
function in these cells. Our studies have demonstrated that varying the extracellular glucose from 3 mM to 
25 mM had no significant effect on the intracellular calcium signaling responses of cells expressing WT or 
mutant Nuf CaSRs.  
We have inserted this data as Supplementary Figure 3 (please see page 6 of the response letter), 
and also inserted the following text in the Results: “…Glucose has recently been reported to lead to allosteric 
activation of the CaSR (30), and we investigated the effect of alterations in glucose concentrations on the 
Ca2+i responses of WT and Nuf mutant Gln723 CaSRs, which were stably expressed in HEK293 cells 
(Supplemental Figure 3). Our findings showed that altering the glucose concentration from 3 mM to 25 mM 
had no effect on the EC50 values of cells stably expressing WT or Nuf mutant Gln723 CaSRs, whereas the 
addition of 40 nM ronacaleret significantly increased the EC50 values of these cells (Supplemental Figure 
3)…”  
Moreover, we have inserted the following text in the Discussion: “…Although our studies showed 
CaSR activation to influence plasma glucose concentrations, we did not observe any effect of extracellular 
glucose on the acute signalling responses of WT or mutant Nuf CaSRs in vitro. Our findings are consistent 
with results obtained by other groups (personal communications from A. Conigrave and D. Ward), but 
contrast with a recent study, which showed that raising the glucose concentration from 3 to 5 mM 
increased the Ca2+i responses of stably expressing HEK293-CaSR cells in the presence of Ca2+o (30). This 
recent study, which showed glucose to act as a CaSR allosteric activator, measured Ca2+i responses in single 
cells using the fluo-8 calcium binding dye (30), whereas, our study measured Ca2+i responses in populations 
of HEK293-CaSR cells using the fluo-4 calcium binding dye; and these methodological differences may be 
contributors to  the contrasting observations of these two studies…” 
We have also inserted the following reference: “…30. Medina J, Nakagawa Y, Nagasawa M, 
Fernandez A, Sakaguchi K, Kitaguchi T, Kojima I. Positive Allosteric Modulation of the Calcium-sensing 
Receptor by Physiological Concentrations of Glucose. J Biol Chem 2016; 291:23126-23135…” 
Furthermore, we have inserted the following Methods text and references in the Supplementary 
section:  
“…Supplemental Methods: Assays to assess glucose as an allosteric modulator were performed in HEK293 
cells that stably expressed either the WT or mutant Gln723 CaSR proteins. These cells were generated using 
HEK293 T-Rex-Flp-in stable cell-lines (Life Technologies), as reported (1). Ca2+o-induced Ca2+i responses were 
measured using Fluo-4 Ca2+ assays adapted from methods previously published (2). Cells were plated in 
poly-L-lysine treated black-walled 96-well plates (Corning), and 12 hours later incubated in media 
containing 1µg/ml tetracycline (Invitrogen) to induce CaSR protein expression. On the following day, cells 
were incubated for 30 min in an extracellular solution composed of 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 
1.3 mM CaCl2 and 10 mM HEPES (pH7.3), and either 3 mM, 5 mM, or 25 mM glucose (all obtained from 
Sigma) (3). Solutions were normalized for osmolarity (by adjusting NaCl concentrations) and pH. For studies 
involving ronacaleret, cells were incubated in an extracellular solution containing 3 mM glucose and 40 nM 
ronacaleret at 37°C. Cells were then loaded with the Fluo-4 Ca2+-binding dye, which was prepared according 
to manufacturer’s instructions (Invitrogen) and incubated for a further 30 min at 37°C (2). The Ca2+i assays 
were performed on a PHERAstar instrument (BMG Labtech) at 37°C with an excitation filter of 485nm and 
an emission filter of 520nm. Baseline measurements were made and increasing doses of CaCl2 (0-15 mM) 
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injected automatically into each well. The peak mean fluorescence ratio of the transient response after each 
individual stimulus was measured using MARS data analysis software (BMG Labtech), and expressed as a 
normalized response. Nonlinear regression of concentration-response curves was performed with GraphPad 
Prism using the normalized response at each [Ca2+]e for each separate experiment for the determination of 
the EC50 (i.e. [Ca2+]e required for 50% of the maximal response). Assays were performed in 8 biological 
replicates for each of the expression constructs. Statistical analysis was performed using the F-test (4).   
Supplemental references: 
1. Babinsky VN et al. Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling 
Abnormalities Associated with G-protein alpha-11 Mutations Causing Hypercalcemic and Hypocalcemic 
Disorders. The Journal of biological chemistry. 2016;291(20):10876-85. 
2. Leach K et al. Towards a structural understanding of allosteric drugs at the human calcium-sensing 
receptor. Cell research. 2016;26(5):574-92. 
3. Medina J et al. Positive Allosteric Modulation of the Calcium-sensing Receptor by Physiological 
Concentrations of Glucose. The Journal of biological chemistry. 2016;291(44):23126-35. 
4. Gorvin CM et al. Galpha11 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy. 
JCI insight. 2017;2(3):e91103…." 
 
Supplementary Figure 3: 
 
 
Supplementary Figure 3. Effect of glucose on the intracellular calcium EC50 values of the WT and Gln723 
(Nuf) mutant CaSRs. HEK293 cells stably expressing the Gln723 mutant CaSR (black bars) showed 
significantly reduced EC50 values compared to HEK293 cells stably expressing WT CaSR (open bars, 
***p<0.001), consistent with a gain-of-function, as previously reported (15,16). Increases in concentrations 
of glucose from 3-25 mM had no effect on the EC50 responses of WT or Gln723 mutant CaSR expressing cells. 
However, both WT and Gln723 mutant CaSR expressing cells responded to treatment with 40 nM 
ronacaleret (Rona) and showed significantly increased EC50 values compared to respective untreated cells 
($$$p<0.001). Data is shown as mean ± 95% confidence intervals of 8 independent transfections. These 
results indicate that glucose is not an allosteric activator of the CaSR. 
 
[Ca] bathing islets in experiments shown in Figures 6B, 6D, 8, and 9 were not specified. 
 
We are grateful to the reviewer for this comment, and to clarify the calcium concentrations the islets were 
incubated in, we have modified the text in the legends to figures 6-9, as follows: 
 
Figure 6B legend: “…Casr+/+ and CasrNuf/Nuf islets were incubated in 1.6 mM [Ca2+]o and exposed to varying 
glucose concentrations (1 mM, 6 mM or 20 mM)…” 
Figure 6D legend: “…Casr+/+ and CasrNuf/Nuf islets were incubated in 1.6 mM [Ca2+]o and exposed to 1 mM and 
6 mM glucose concentrations…” 
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Figure 7 legend: “…Representative membrane potential recording of β-cells from intact Casr+/+ and 
CasrNuf/Nuf after islets had been incubated in 1.5 mM [Ca2+]o…” 
Figure 8 legend: “…Representative recording of β-cell KATP channel conductance from intact Casr+/+ and 
CasrNuf/Nuf islets after islets had been incubated in 1.5 mM [Ca2+]o…” 
Figure 9 legend: “…Representative membrane potential recording of α-cells from (A) intact Casr+/+ and (B) 
CasrNuf/Nuf islets after islets had been incubated in 1.5 mM [Ca2+]o…” 
 
Figure 8A and 8C can be combined, so can Figures 8B and 8D. 
 
We thank the reviewer for this helpful comment, and have combined these panels in Figure 8 (please see 
amended figure on page 12 of the response letter). 
 
Please verify statistics for the data in Supplementary Figure 4.  Some gene expression (e.g., Ccnd2, Foxm1, 
and Foxo1) appears to be different between wt and Nuf islets. 
 
We are grateful to the reviewer for this comment, and would like to verify that we used the Kruskal-Wallis 
test for multiple comparisons when analysing this data. No significant differences were observed between 
Casr+/+ and CasrNuf/Nuf islets, and we have inserted the following the text in the legend to Supplementary 
figure 4 (now relabelled as Supplementary figure 5): “…Alterations in gene expression between CasrNuf/Nuf 
and Casr+/+ islets were assessed using the Kruskal-Wallis test for multiple comparisons…” 
 
 
Figures with amended sample sizes are shown on pages 8-14. The sample numbers that have been 
increased from n=3-13 to n=5-14 biological replicates are highlighted in yellow.  
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Supplementary Figure 1. Body weight and comp osition of Nuf mice. (A-B) Body weight of male 
and female Casr+/+ and CasrNuf/Nuf mice. (C-D) Percentage fat mass of male and female Casr+/+ and 
CasrNuf/Nuf mice. (E-F) Percentage lean mass of male and female Casr+/+ and CasrNuf/Nuf mice. 
Results are expressed as mean ± SEM. 
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Supplementary Figure 4
Supplementary Figure 4. Comparison of bioch emical responses of ronacaleret-treated male and 
female mice. (A) Maximal changes in plasma adjusted-cal cium concentrations of ronacalceret-treated 
male and female Casr+/+, CasrNuf/+ and CasrNuf/Nuf mice. Maximal changes in plasma concentrations 
of (B) glucose, (C) insulin and (D) glucagon of ronacalcer et-treated male and female Casr+/+, CasrNuf/+ 
and CasrNuf/Nuf mice during IPGTT. Mean ± SEM values are represented by solid bars. NS, non-significant.
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Reviewer #2: General Statement: 
This is a study that evaluated the role of the calcium-sensing receptor (CaSR) in glucose homeostasis in a 
Casrnuf/+ and Casrnuf/nuf mice, an animal model of autosomal dominant hypocalcemia.  The study also 
looked at the effects of a CaSR antagonist compound, a calcilytic, on glucose homeostasis.  The authors 
found that the Casrnuf/+ and Casrnuf/nuf mice, which have either one or two germline gain-of-function 
mutations in the CaSR, respectively, had impaired glucose tolerance and insulin secretion.  Treatment with 
the calcilytic improved glucose intolerance.  Mutant mice had decreased pancreatic islet mass and β-cell 
proliferation.  There was also evidence for impaired glucagon suppression in response to glucose as well as 
increased pancreatic α-cells.  The studies were methodically and rigorously conducted and the manuscript 
easy to read and well-written.  While there is little evidence that these findings translate to humans with 
activating mutations in the CaSR, it suggests that the CaSR may play a role in glucose homeostasis in 
mammals. 
 
We thank the Reviewer for the supportive comments that “…The studies were methodically and rigorously 
conducted and the manuscript easy to read and well-written…” and “…suggests that the CaSR may play a 
role in glucose homeostasis in mammals…” 
Results: 
There was a tendency to overstate some of the results: 
1. On page 11, lines 14-16, please clarify the results of the change in insulin concentrations following 
glucose bolus.  Only male Casrnuf/+ mice had statistically different insulin levels than the Casr+/+ mice.  
 
We thank the Reviewer, and have clarified the change in insulin concentrations in male and female mice by 
modifying the Results text, as follows: “…Plasma insulin concentrations of male and female Casr+/+ mice 
increased two-fold at 10 min after an IP 2g/kg glucose bolus injection (Figure 1C-D). However, male affected 
CasrNuf/+ and CasrNuf/Nuf mice showed significantly reduced plasma insulin concentrations at 10 and 20 min 
following glucose administration (Figure 1C); whereas only female CasrNuf/Nuf mice showed significantly 
reduced insulin concentrations at 20 min (Figure 1D), compared to respective Casr+/+ mice…” 
 
2.  On page 11, lines 16-18, it appears that the female Casrnuf/nuf mice only had one insulin level that 
was statistically different from the Casr+/+ mice.  Please temper wording of "Casrnuf/nuf had no significant 
insulin response" and the following sentence, "Thus, plasma insulin concentrations were significantly 
reduced in Nuf mice compared to Casr+/+". 
 
We are grateful to the reviewer for these helpful comments, and have omitted "Casrnuf/nuf had no 
significant insulin response" from the Results text. Moreover, we have specified which Nuf mice had reduced 
insulin concentrations by inserting the following text in the Results: “…male affected CasrNuf/+ and CasrNuf/Nuf 
mice showed significantly reduced plasma insulin concentrations at 10 and 20 min following glucose 
administration (Figure 1C); whereas only female CasrNuf/Nuf mice showed significantly reduced insulin 
concentrations at 20 min (Figure 1D), compared to respective Casr+/+ mice…” 
 
3. On page 11, lines 18-20, please note that the glucagon response was only statistically different at 
one time point, and clarify the difference between males and females. 
 
We thank the Reviewer, and to address this comment have modified the Results text, as follows: “…Affected 
male CasrNuf/Nuf mice were also shown to have an inadequate suppression of plasma glucagon 
concentrations at the 30 min time-point during a 120 min IPGTT (Figure 1E), whereas female CasrNuf/Nuf mice 
had significantly raised plasma glucagon concentrations at 120 min (Figure 1F)…” 
 
4. On page 12, lines 18-20, please note the gender differences in the effect of ronacaleret treatment 
on glucose tolerance in Casrnuf/+ mice. 
 
We thank the Reviewer, and have inserted the following text in the Results: “…Moreover, gender differences 
were noted, as ronacaleret normalised plasma glucose concentrations at 30 min in male CasrNuf/+mice, but 
only at 60 min in female CasrNuf/+mice (Figures 3 and 4)…” 
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Discussion:   
1. In the first paragraph on page 17, lines 3-12, please add that there is no obvious glucose 
homeostasis phenotype in the patients with ADH-causing mutations (i.e., patients in the literature are not 
reported to have diabetes) and further, more detailed investigation of glucose homeostasis in humans is 
warranted. 
 
We are grateful to the reviewer for this comment, and have inserted the following text in the Discussion: 
“…However, impaired glucose tolerance or diabetes has not been reported in ADH patients to-date, and 
detailed investigations of glucose homeostasis in humans are warranted…” 
 
2. On page 20, lines 3-5, it seems that one of the "Casrnuf/nuf" should be "Casr+/+" α-cells.  Please 
clarify.   
 
We are grateful to the reviewer for detecting this error and have amended this to “…Casr+/+ α-cells…” 
 
Figure 2: 
1.  In Figure 2B, please change the lines so that they are different colors.  Given the overlap of the 
dashed lines and circular symbols, it is difficult to differentiate between the various lines in both the full 
graph as well as the zoomed-in image.   
 
We thank the Reviewer, and have amended figure 2B, so that the lines are all different colours (please see 
below). 
 
 
   
Figure 6:  
1. In panel D, there appears to be an extra number included for the "N" in both groups of 
mice.  Please clarify what the middle "N" number between the glucose 1mM and 6 mM is representing.   
 
We are grateful to the reviewer for detecting this error, and have deleted the additional “N” number from 
figure 6D (please see below). 
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Figure 7:  
1. In the legend on page 27, lines 14-15, please clarify whether or not p-values are compared to 
Casr+/+ mice at respective glucose concentrations alone or respective glucose and calcium 
concentrations.   
 
We thank the reviewer, and have clarified this by amending the figure 7 legend, as follows: “…**p <0.01 
compared to Casr+/+ mice at respective glucose and Ca2+o concentrations…” 
 
Figure 9: 
1. In the legend on page 28, line 1, please change "12 mM (12G) and 20 mM (20G)" to "6 mM (6G)".   
 
We are grateful to the reviewer for detecting this error, and have amended the glucose concentrations to 
“…1 mM (1G) and 6 mM (6G)…” 
 
2. It is stated that p-values are compared to Casr+/+ mice at respective glucose concentrations.  In 
panel C and D, are the Casr+/+ mice at glucose 6 mM and with tolbutamide being compared to the Casr+/+ 
mice at glucose 1mM?  Please clarify these p-values. 
 
We thank the reviewer for this comment, and confirm that the Casr+/+ mice at 6 mM glucose and with 
tolbutamide are being compared to the Casr+/+ mice at 1mM glucose. We have amended the figure 9 
legend to clarify this, as follows: “…*p <0.05, **p <0.01 compared to respective α-cells at 1 mM glucose…” 
 
We thank the editors and reviewers for their comments and have aimed to comply with all of the requested 
revisions. We will be glad to provide further information if required.  
 
With best wishes, 
 
Yours sincerely, 
 
Professor R V Thakker 
May Professor of Medicine 
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Abstract 1 
 2 
The calcium-sensing receptor (CaSR) is a family C G-protein-coupled receptor (GPCR) that plays a 3 
pivotal role in extracellular calcium homeostasis. The CaSR is also highly expressed in pancreatic islet 4 
α- and β-cells that secrete glucagon and insulin, respectively. To determine whether the CaSR may 5 
influence systemic glucose homeostasis, we characterized a mouse model with a germline gain-of-6 
function CaSR mutation, Leu723Gln, referred to as Nuclear flecks (Nuf). Heterozygous- (CasrNuf/+) 7 
and homozygous-affected (CasrNuf/Nuf) mice were shown to have hypocalcemia in association with 8 
impaired glucose tolerance and insulin secretion. Oral administration of a CaSR antagonist compound, 9 
known as a calcilytic, rectified the glucose intolerance and hypoinsulinemia of CasrNuf/+ mice, and 10 
ameliorated glucose intolerance in CasrNuf/Nuf mice. Ex vivo studies showed CasrNuf/+ and CasrNuf/Nuf 11 
mice to have reduced pancreatic islet mass and β-cell proliferation. Electrophysiological analysis of 12 
isolated CasrNuf/Nuf islets showed CaSR activation to increase the basal electrical activity of β-cells 13 
independently of effects on the activity of the ATP-sensitive K+ (KATP) channel. Casr
Nuf/Nuf mice also 14 
had impaired glucose-mediated suppression of glucagon secretion, which was associated with 15 
increased numbers of α-cells and a higher α-cell proliferation rate. Moreover, CasrNuf/Nuf islet 16 
electrophysiology demonstrated an impairment of α-cell membrane depolarization in association with 17 
attenuated α-cell basal KATP channel activity. These studies indicate that the CaSR activation impairs 18 
glucose tolerance by a combination of α- and -cell defects and also influences pancreatic islet mass. 19 
Moreover, our findings highlight a potential application of targeted CaSR compounds for modulating 20 
glucose metabolism. 21 
 22 
Précis: Mice with a germline gain-of-function CaSR mutation have hypoinsulinemia, 23 
hyperglucagonemia, reduced pancreatic islet mass; and impaired glucose tolerance, which is 24 
rectifiable by calcilytic therapy.  25 
 4 
Introduction 1 
 2 
Glucose homeostasis is tightly regulated by the joint actions of insulin and glucagon, which are 3 
secreted from the pancreatic islet β- and α-cells, respectively (1,2). Diabetes mellitus is a bihormonal 4 
disorder which affects >330 million people worldwide, and is characterized by reduced insulin 5 
secretion and aberrant glucagon secretion, which arises from alterations in islet function as well as 6 
mass (1,2). G-protein-coupled receptors (GPCRs), which comprise the largest superfamily within the 7 
human proteome and are targeted by 40% of all currently approved drugs (3), facilitate the effects of 8 
diverse extracellular stimuli, ranging from fatty acids to neurotransmitters and gut hormones, on α- 9 
and β-cells and represent an exploitable target for the modulation of glucose homeostasis (4,5). The 10 
extracellular calcium (Ca2+o)-sensing receptor (CaSR) is a family C GPCR that plays a key role in the 11 
parathyroid and renal regulation of Ca2+o homeostasis by: coupling to intracellular signal transduction 12 
cascades that include the Gq/11-mediated stimulation of phospholipase C (PLC), which increases 13 
inositol 1,4,5-trisphosphate (IP3), thereby leading to a rapid rise in cytosolic calcium (Ca2+i) 14 
concentrations; and activating the MAPK pathway (6). The CaSR is also highly expressed in 15 
pancreatic islet α- and β-cells (7,8), and studies involving isolated human islets and insulin-secreting 16 
cell lines have shown that activation of the CaSR following exposure to elevated Ca2+o concentrations 17 
or allosteric activators triggers transient stimulations of insulin and glucagon secretion, which were 18 
associated with upregulation of PLC and MAPK-mediated signaling responses (8-10). Moreover, a 19 
study involving wild-type (WT) mice has demonstrated pancreatic islet CaSR expression to be 20 
associated with insulin secretion in vivo (11). However, the role of this GPCR in systemic glucose 21 
homeostasis is unclear. For example, one patient-based association study has reported a common 22 
coding-region CaSR gene variant to be an independent determinant of plasma glucose concentrations 23 
(12), whilst another study of patients with familial hypocalciuric hypercalcemia (FHH), which is 24 
caused by germline loss-of-function CaSR mutations, did not reveal any alterations in glucose 25 
tolerance or insulin secretion (13). However, it may be that gain-of-function CaSR mutations, which 26 
cause autosomal dominant hypocalcemia (ADH) (14), are associated with abnormalities of glucose 27 
homeostasis and not FHH-associated loss-of-function CaSR mutations. To investigate this possibility, 28 
 5 
we have evaluated glucose tolerance and pancreatic islet function in a mouse model for ADH due to a 1 
germline gain-of-function CaSR mutation, Leu723Gln, referred to as Nuclear flecks (Nuf) because the 2 
mouse was initially identified to have cataracts (15,16). Our analysis of these Nuf mice has 3 
demonstrated a role for the CaSR in glucose homeostasis 4 
  5 
 6 
Materials and Methods 1 
 2 
Animals 3 
All study animals were litter-mates aged between 20-28 weeks and kept in accordance with Home 4 
Office welfare guidance in an environment controlled for light (12 hours light and dark cycle), 5 
temperature (21 ± 2°C) and humidity (55 ± 10%) at the Medical Research Council (MRC) Harwell 6 
Centre. Mice had free access to water (25 ppm chlorine) and were fed ad libitum on a commercial diet 7 
(RM3, Special Diet Services, UK) that contained 1.24% calcium, 0.83% phosphorus and 2948 IU/kg 8 
of vitamin D. Nuf mice were maintained on the inbred 102/H background, which is a substrain bred at 9 
the Mary Lyon Centre (Harwell, UK (15,16). Animal studies were carried out in accordance with 10 
GlaxoSmithKline policy on the care, welfare and treatment of animals, approved by the MRC Harwell 11 
Institute Ethical Review Committee, and were licensed under the Animal (Scientific Procedures) Act 12 
1986, issued by the UK Government Home Office Department (PPL30/2752). 13 
 14 
Compounds 15 
Ronacaleret, which is also known as SB-751689, was provided by GlaxoSmithKline and dissolved in a 16 
20% aqueous solution of 2-hydroxypropyl--cyclodextrin (Sigma-Aldrich, catalog no. H107) prior to 17 
use in in vitro and in vivo studies.  18 
 19 
Cell culture and transfection 20 
Human embryonic kidney (HEK) 293 cells were cultured in high-glucose DMEM (Invitrogen) 21 
supplemented with 10% fetal bovine serum (FBS), as described (17). WT (Leu723) and mutant 22 
(Gln723) CaSR-pEGFP-N1 constructs were generated, as reported (16), and transiently transfected 23 
into HEK293 cells using Lipofectamine Plus (Invitrogen), as described (16). Successful transfection of 24 
WT and mutant CaSR proteins were confirmed was confirmed by visualising green fluorescence 25 
protein (GFP) fluorescence using an Eclipse E400 fluorescence microscope with an epifluorescence 26 
filter, and images were captured using a DXM1200C digital camera and NIS Elements software 27 
(Nikon), as described (17).  28 
 7 
Measurement of Ca2+i responses 1 
The effect of ronacaleret on the Ca2+i responses of CaSR-expressing cells was assessed by a flow 2 
cytometry-based assay, as reported (17,18). In brief, 48 hours after transfection, the cells were 3 
harvested, washed in calcium- and magnesium-free Hank’s balanced salt solution (HBSS, Invitrogen) 4 
and loaded with 1μg/ml indo-1-acetoxymethylester (Indo-1-AM) (Molecular Probes) for 1 hour at 375 
°C (17,18). After the removal of free dye, the cells were resuspended in calcium- and magnesium-6 
free HBSS and maintained at 37°C. Transfected cells were incubated with either a 20% aqueous 7 
solution of 2-hydoxypropyl-β-cyclodextrin (vehicle), or ronacaleret at concentrations of 20 and 40nM 8 
for 1 hour, as described (18). Flow cytometry was performed using a Beckman Coulter MoFlo XDP 9 
equipped with JDSUY Xcyte UV Laser and a Coherent Sapphire 488 Laser with a 550LP dichroic 10 
mirror and 580/30 bandpass filter (17). Single cells were isolated and stimulated by sequentially 11 
adding calcium to increase the Ca2+o concentration ([Ca2+]o) in a stepwise manner from 0-15 mM. The 12 
baseline fluorescence ratio was measured for 2 min, the fluorescence ratio compared to the time was 13 
recorded and data were collected for 2 min at each [Ca2+]o, as described (17,18). Cytomation Summit 14 
software was used to determine the peak mean fluorescence ratio of the transient response after each 15 
individual stimulus, which was expressed as a percentage normalized response (17,18). Nonlinear 16 
regression of the concentration-response curves was performed with GraphPad Prism (GraphPad) to 17 
calculate the half-maximal (EC50) responses for each separate experiment (17). 18 
 19 
Effect of ronacaleret on the glucose tolerance of Nuf mice 20 
Ronacaleret (20 mg/ml) or drug vehicle was administered by twice daily oral gavage to mice over a 5-21 
day period. The mice were then tested using the international mouse phenotyping consortium (IMPC) 22 
glucose tolerance test protocol (https://www.mousephenotype.org/impress/protocol/87/7). Briefly, 23 
mice were fasted for 16 hours, and a blood sample obtained before IP administration of a 2g/kg 24 
glucose load. Subsequent blood samples were taken at 30, 60 and 120 min for plasma glucose and 25 
glucagon measurements; or at 10, 20, and 30 min for plasma insulin measurements, as described (19). 26 
 27 
  28 
 8 
Body composition analysis 1 
Fat and lean body mass of non-anaesthetized live mice were measured using the Echo-MRI Analyzer 2 
system (Echo Medical Systems, Houston, TX), as described (20).  3 
 4 
Islet insulin and glucagon secretion 5 
Pancreatic islets were isolated from whole mouse pancreata by collagenase digestion and separated 6 
from the suspension, as described (19). Islets were used for secretion experiments within 2 hours of 7 
isolation. Batches of 13 size-matched islets were incubated for 1 hour at 37°C in 0.3 ml of modiﬁed 8 
Krebs-Ringer buffer containing 2mg/ml BSA, 1.6 mM CaCl2 and 3mM glucose, followed by a 1 hour 9 
incubation in 0.3 ml of the same Krebs-Ringer buffer supplemented with 1, 6 or 20 mM glucose, as 10 
described (21). A Krebs-Ringer buffer containing 0.8 mM CaCl2 was used to evaluate the effect of 11 
lowering the [Ca2+]o on islet hormone secretion. The supernatant was used for measurement of 12 
secreted insulin and glucagon, and islets were lysed in cold acid ethanol for measurement of insulin 13 
and glucagon content. Insulin and glucagon was determined by radioimmunoassay (Millipore UK Ltd, 14 
Livingstone, UK) or using a Rat/Mouse Insulin, Glucagon duplex ELISA (Meso Scale Discovery). 15 
 16 
Quantitative RT-PCR 17 
Total RNA from isolated islets was extracted using an RNeasy mini-kit (Qiagen) and cDNA was 18 
generated by the Superscript II enzyme (Invitrogen), as described (19). QuantiTect primer assays were 19 
used to amplify selected genes (Arx, Ccnd2, Foxm1, Foxo1, Irx2, Nkx6, Pax4, Pax6, Pdx1, Tcf7l2), 20 
which were analyzed by quantitative RT-PCR (qRT-PCR) using SYBR Green (Qiagen) on the 21 
StepOnePlus qRT-PCR system (Life Technologies), as described (22). The ΔΔCt method was used to 22 
calculate fold change alterations in gene expression, relative to a housekeeping panel comprising the 23 
Actb, Eef1b2, and Gapdh genes (22). 24 
 25 
Biochemical analysis 26 
Blood samples were collected from the lateral tail vein of study mice following application of topical 27 
local anesthesia, as reported (23), or collected from the retro-orbital vein under isoflurane terminal 28 
 9 
anesthesia. Plasma was separated by centrifugation at 5000 g for 10 min at 8C, and analysed for 1 
calcium and albumin on a Beckman Coulter AU680 analyzer, as described (15). Plasma calcium was 2 
adjusted for variations in albumin concentrations using the formula: (plasma calcium (mmol/l) – 3 
[(plasma albumin (g/l) – 30) x 0.02], as reported (23). Plasma glucose concentrations were measured 4 
using an Analox GM9 analyzer, as described (19). Plasma insulin concentrations were measured using 5 
a Rat/Mouse Insulin ELISA (Millipore), as described (19), and plasma glucagon concentrations 6 
measured using a Rat/Mouse Glucagon ELISA (Mercodia).  7 
 8 
Islet electrophysiology 9 
Electrical activity was measured from α- and -cells within intact mouse islets using the perforated-10 
patch technique, as described (24), and all measurements were obtained at 34˚C. Islets were 11 
immobilised using a wide-bore glass suction pipette (24) and perfused with modified Krebs-Ringer 12 
solution (140 mM NaCl, 3.6 mM KCl, 1.5 mM CaCl2, 0.5 mM MgSO4, 10 mM HEPES, 0.5 mM 13 
NaH2PO4 and NaHCO3 at pH 7.4 with NaOH, and glucose as indicated), as reported (25). A Krebs-14 
Ringer solution containing 0.75 mM CaCl2 was used to evaluate the effect of lowering the [Ca2+]o on 15 
islet electrical activity. The solution within the pipet contained 76 mM K2SO4, 10 mM KCl, 10 mM 16 
NaCl, 1 mM MgCl2, 5 mM HEPES (pH 7.35 using KOH) (24). To perforate the cell membrane, 17 
amphotericin B (6 g/ml) was added to the intracellular buffer. The conductance of the β-cell ATP-18 
sensitive K+ (KATP) channel within intact islets was measured using the perforated patch clamping 19 
technique following exposure to different glucose concentrations or to tolbutamide (24). During the 20 
KATP channel conductance studies, β-cells were held at -70 mV, and K+ currents were evoked by 21 
exposing the cells to alternating 50 ms pulses of -60 or -80 mV (25). Islet cell types were established 22 
by their electrical activity in response to glucose, and cells that were electrically active at 1 mM 23 
glucose were identified as α-cells (26). Furthermore, β-cells were distinguished from non--cells by 24 
the absence of a voltage-gated Na+-current when a transient pulse from -70 mV to 0 mV was applied 25 
(21). Measurements were undertaken in individual islets using EPC-10 patch-clamp amplifier (HEKA 26 
Electronics, http://www.heka.com/) and Pulse software (version 8.50) as described previously (24). 27 
 28 
 10 
Islet area analysis  1 
Mouse pancreata were fixed in 10% neutral buffered formalin, mounted longitudinally and paraffin 2 
embedded, as described (19). Serial sections (4.5µm) were cut and every 10th section stained with 3 
H&E, as described (19). Images of ≥10 H&E-stained sections per mouse were acquired at a 20x 4 
magnification using the semi-automated TissueFax slide-scanning microscope (TissueGnostics, 5 
Austria), as described (27). Islets were identified and islet area, size and number quantified using 6 
HistoQuest software (TissueGnostics, Austria) (27). Islet area was normalised to the total section area 7 
and to body weight, and islet size was calculated by dividing the total islet area per section by the 8 
number of islets on the same section. 9 
 10 
Islet immunohistochemistry 11 
Immunohistochemistry was undertaken using paraffin-embedded pancreatic sections that had been 12 
subjected to heat-induced epitope retrieval in citrate buffer (pH 6.0), followed by blocking in 10% 13 
donkey serum for 1 hour. Primary antibodies used for insulin, glucagon, and Ki-67 staining were 14 
guinea pig anti-insulin (1:200, abcam - ab7842 (RRID: AB_306130)) rabbit anti-glucagon (1:200, 15 
abcam - ab92517 (RRID: AB_10561971)), and rabbit anti-Ki67 (1:500, abcam - ab15580 (RRID: 16 
AB_443209)), respectively. Secondary antibodies used were donkey anti-guinea pig (Jackson: 706-17 
225-148, Cy2 (RRID: AB_2340467)) 1: 100, and donkey anti-rabbit (Jackson: 711-165-152, Cy3 18 
(RRID: AB_2307443)) 1:500, in PBS. Sections were mounted in prolong Gold anti-fade reagent 19 
containing DAPI (Life Technologies). Images of whole sections were acquired using the TissueFax 20 
slide-scanning microscope TissueFax (TissueGnostics, Austria), as described (27). Quantification of 21 
immunofluorescence signals was undertaken using the semi-automated intensity detection function of 22 
the TissueQuest software (TissueGnostics, Austria), as described (27). The numbers of α- and -cells 23 
within individual islets were quantified using the cell-based analysis profile of the TissueQuest 24 
software (27), and normalized to the total islet area, and reported as percentage of the mean numbers 25 
of Casr+/+ α- and -cells, respectively. 26 
 27 
 28 
 11 
 1 
Statistical analysis 2 
The in vitro studies involved two separate transfection experiments and 8-9 technical assays. 3 
Statistical comparisons of the EC50 responses were undertaken using the F-test (17,18). For the in vivo 4 
and ex vivo studies, the Mann-Whitney U test was used to compare differences between two groups, 5 
and the Kruskal-Wallis test was used to compare multiple groups. An unpaired Student’s t-test was 6 
used to compare groups with small sample sizes (n < 5), as reported (28). All analyses were 7 
undertaken using GraphPad Prism (GraphPad), and a value of p < 0.05 was considered significant for 8 
all analyses.  9 
  10 
 12 
Results 1 
 2 
Nuf mice have impaired glucose tolerance that is ameliorated by a CaSR allosteric modulator 3 
To establish whether the gain-of-function CaSR mutation in Nuf mice may be associated with 4 
alterations in glucose homeostasis, IP glucose tolerance testing (IPGTT) was performed on WT 5 
(Casr+/+), heterozygous- (CasrNuf/+) and homozygous-affected (CasrNuf/Nuf) mice aged 20-28 weeks that 6 
had been fasted for 16 hours. Plasma glucose concentrations were measured at 0, 30, 60 and 120 min 7 
following an IP 2g/kg glucose bolus injection. Male and female CasrNuf/+ and CasrCasrNuf/Nuf mice had 8 
elevated plasma glucose concentrations at 30 and 60 min, which were significantly (p < 0.01) greater 9 
than those of respective Casr+/+ mice (Figure 1A-B). The impaired glucose tolerance was not 10 
associated with any alterations in body weight, or in fat or lean mass (Supplemental Figure 1). To test 11 
whether the impaired glucose tolerance of Nuf mice may be associated with abnormalities of insulin 12 
secretion in vivo, an IPGTT was conducted with plasma samples collected for insulin measurement at 13 
0, 10, 20 and 30 min. Plasma insulin concentrations of male and female Casr+/+ mice increased two-14 
fold at 10 min after an IP 2g/kg glucose bolus injection (Figure 1C-D). However, male affected 15 
CasrNuf/+ and CasrNuf/Nuf mice showed significantly reduced plasma insulin concentrations at 10 and 20 16 
min following glucose administration (Figure 1C); whereas only female CasrNuf/Nuf mice showed 17 
significantly reduced insulin concentrations at 20 min (Figure 1D), compared to respective Casr+/+ 18 
mice. Affected male CasrNuf/Nuf mice were also shown to have an inadequate suppression of plasma 19 
glucagon concentrations at the 30 min time-point during a 120 min IPGTT (Figure 1E), whereas 20 
female CasrNuf/Nuf mice had significantly raised plasma glucagon concentrations at 120 min (Figure 21 
1F). No significant differences in the glucose, insulin or glucagon responses were noted between male 22 
and female mice (Supplemental Figure 2).  23 
 To investigate if the impaired glucose tolerance of Nuf mice, which have the Leu723Gln gain-24 
of-function CaSR mutation, could be corrected by a selective CaSR negative allosteric modulator i.e. 25 
calcilytic agent, we assessed the in vitro and in vivo effects of ronacaleret, a calcilytic compound (29). 26 
For the in vitro studies, HEK293 cells were transiently transfected with WT (Leu723) or mutant 27 
(Gln723) CASR-pEGFP-N1 constructs, which express the CaSR protein fused to the N-terminus of 28 
 13 
enhanced GFP (EGFP) (16), and the effect of ronacaleret on the responses of Ca2+i concentrations to 1 
alterations in [Ca2+]o was assessed. HEK293 cells expressing the mutant Gln723 CaSR (Figure 2A) 2 
were shown to have a leftward shift of the concentration-response curve (Figure 2B) with a significant 3 
reduction in EC50 (2.63 ± 0.08 mM), compared to WT (2.92 ± 0.06 mM; p < 0.01) (Figure 2C), 4 
consistent with a gain-of-function, as reported (16). A dose titration of ronacaleret revealed 20 nM and 5 
40 nM concentrations of this calcilytic compound to normalise the EC50 values and shift in the 6 
concentration-response curve of mutant Gln723-expressing cells (Figure 2B-C). Glucose has recently 7 
been reported to lead to allosteric activation of the CaSR (30), and we investigated the effect of 8 
alterations in glucose concentrations on the Ca2+i responses of WT and Nuf mutant Gln723 CaSRs, 9 
which were stably expressed in HEK293 cells (Supplemental Figure 3). Our findings showed that 10 
altering the glucose concentration from 3 mM to 25 mM had no effect on the EC50 values of cells 11 
stably expressing WT or Nuf mutant Gln723 CaSRs, whereas the addition of 40 nM ronacaleret 12 
significantly increased the EC50 values of these cells (Supplemental Figure 3). To determine whether 13 
amelioration of CaSR gain-of-function by ronacaleret, may lead to an improvement in glucose 14 
tolerance in vivo, we administered this calcilytic agent to Nuf mice. Male and female Casr+/+, CasrNuf/+ 15 
and CasrNuf/Nuf mice were given ronacaleret or drug vehicle for 5-days by twice daily oral-gavage. 16 
Ronacaleret was administered at a dose of 90 mg/kg, as pilot studies had shown this dose to increase 17 
plasma calcium concentrations and to be well tolerated in Casr+/+ mice. Untreated CasrNuf/+ and 18 
CasrNuf/Nuf mice were shown to be significantly hypocalcemic compared to Casr+/+ mice, and CasrNuf/Nuf 19 
mice had significantly lower plasma calcium concentrations than CasrNuf/+ mice (Figure 2D-E). 20 
Ronacaleret treatment significantly (p < 0.01) increased plasma calcium concentrations in male and 21 
female Casr+/+, CasrNuf/+ and CasrNuf/Nuf mice compared to respective untreated mice (Figure 2D-E). 22 
Ronacaleret treatment normalised the plasma calcium concentrations of male and female CasrNuf/+ 23 
mice (Figure 2D-E). However, the plasma calcium concentrations of treated CasrNuf/Nuf mice remained 24 
significantly reduced compared to untreated Casr+/+ mice (Figure 2D-E). Ronacaleret treatment had no 25 
effect on the plasma glucose concentrations of male and female Casr+/+ mice (Figures 3 and 4), but 26 
significantly (p < 0.05) improved glucose tolerance in male and female CasrNuf/+ and CasrNuf/Nuf mice 27 
compared to respective mice treated with the drug vehicle alone (Figures 3 and 4). Moreover, gender 28 
 14 
differences were noted, as ronacaleret normalised plasma glucose concentrations at 30 min in male 1 
CasrNuf/+mice, but only at 60 min in female CasrNuf/+mice (Figures 3 and 4). Ronacaleret treatment had 2 
no effect on the plasma insulin concentrations of male and female Casr+/+ mice (Figures 3 and 4), but 3 
significantly increased the plasma insulin concentrations of male and female CasrNuf/+ mice compared 4 
to untreated CasrNuf/+ mice (Figures 3 and 4). Ronacaleret treatment did not alter plasma insulin 5 
concentrations in male and female CasrNuf/Nuf mice (Figures 3 and 4), and had no significant effect on 6 
the plasma glucagon concentrations of male and female Casr+/+, CasrNuf/+ or CasrNuf/Nuf mice (Figures 3 7 
and 4). No significant differences were noted between the biochemical responses of ronacaleret-8 
treated male and female mice (Supplemental Figure 3). To evaluate the mechanisms underlying these 9 
alterations of glucose tolerance, and plasma insulin and glucagon concentrations in Nuf mice, further 10 
ex vivo and electrophysiological studies were undertaken. As no significant differences had been 11 
observed for the glucose, insulin and glucagon responses of male and female mice, the ex vivo data 12 
were combined for males and females. 13 
 14 
Pancreatic islet size and proliferation 15 
We assessed for alterations in islet morphology by undertaking histological analysis of whole 16 
pancreases from adult Casr+/+, CasrNuf/+ and CasrNuf/Nuf mice. This revealed that the overall architecture 17 
of CasrNuf/+ and CasrNuf/Nuf islets was similar to that in Casr+/+ mice (Figure 5A). However, islet area, 18 
which was normalised to body weight, was reduced by >40% in CasrNuf/+ and CasrNuf/Nuf mice (Figure 19 
5B), and this was associated with significant decreases in islet numbers and mean islet size (Figure 20 
5C-D). To assess, whether the reduced islet area may also be associated with alterations in the 21 
numbers of β-cells or α-cells, whole pancreas sections were immunostained for insulin and glucagon 22 
(Figure 5E). Individual islets from CasrNuf/Nuf mice had 5-10% fewer β-cells (p < 0.05) and ~20% more 23 
α-cells than Casr+/+ islets (p < 0.05) (Figure 5F-G). To investigate whether the reduction in β-cells and 24 
increase in α-cells were caused by alterations in cellular proliferation, whole pancreas sections were 25 
immunostained with the proliferation marker Ki-67. (Figure 5H). The percentage of proliferating 26 
insulin-positive β-cells in CasrNuf/Nuf mice was found to be significantly decreased (p < 0.05), whereas 27 
the percentage of proliferating insulin-negative cells (which are predominantly α-cells) was 28 
 15 
significantly increased when compared to respective Casr+/+ islets (Figure 5I-J). Quantitative RT-PCR 1 
analysis utilising RNA from isolated Casr+/+ and CasrNuf/Nuf islets revealed that these changes in β-cell 2 
and α-cell proliferation were not associated with significant alterations in the expression of genes 3 
regulating islet mass such as Foxo1, Foxm1, Ngn3, and Tcf7l2 (31-34), which promote β-cell 4 
proliferation; or in the expression of genes such as Arx and Irx2 (35), which influence α-cell 5 
proliferation (Supplemental Figure 4). 6 
 7 
Insulin and glucagon secretion from isolated islets 8 
To determine whether Nuf mice have alterations in pancreatic islet insulin secretion, size-matched 9 
islets were isolated from Casr+/+ and CasrNuf/Nuf mice, and exposed to low (1 mM), physiological (6 10 
mM) or high (20 mM) glucose concentrations in the presence of 1.6 mM [Ca2+]o, which represents a 11 
physiological [Ca2+]o (36). The insulin content of isolated Casr
Nuf/Nuf islets was not significantly 12 
different from isolated Casr+/+ islets (Figure 6A). Measurement of insulin in the supernatant of islets 13 
following glucose stimulation did not reveal any impairment in the insulin secretory responses of 14 
isolated CasrNuf/Nuf islets compared to Casr+/+ islets (Figure 6B). We also investigated whether 15 
glucagon secretion may be altered in Nuf mouse islets. Compared to Casr+/+ islets, there was a >30% 16 
increase in the glucagon content (Figure 6C) of CasrNuf/Nuf islets. Increasing glucose from 1 to 6 mM 17 
resulted in a 60% reduction of glucagon secretion from isolated Casr+/+ islets (Figure 6D). In contrast, 18 
islets from CasrNuf/Nuf mice exhibited a lack of glucose-induced suppression of glucagon release 19 
(Figure 6D), which is consistent with that observed in islets from type 2 diabetic patients (37). To 20 
investigate whether the reduced plasma insulin concentrations of Nuf mice may have been a 21 
consequence of their hypocalcemia, insulin secretion from isolated islets was measured following 22 
exposure to 0.8 mM [Ca2+]o, which is similar to the plasma calcium concentrations observed in 23 
CasrNuf/Nuf mice (15,16). Altering the [Ca2+]o had no effect on insulin secretion in the presence of low 24 
(1 mM) glucose concentrations (Figure 6E). However, exposure to low (0.8 mM) Ca2+o impaired 25 
insulin secretion from Casr+/+ and CasrNuf/Nuf islets in the presence of high (20 mM) glucose 26 
concentrations (Figure 6E). Exposure to low (0.8 mM) Ca2+o increased glucagon secretion from 27 
 16 
Casr+/+ islets at 20 mM glucose, but had no effect on glucagon secretion from CasrNuf/Nuf islets (Figure 1 
6F). 2 
Electrophysiological studies of isolated islets. We investigated for alterations in β-cell electrical 3 
activity by recording the membrane potential of β-cells within intact Casr+/+ and CasrNuf/Nuf islets upon 4 
treatment with varying (1 mM, 12 mM or 20 mM) concentrations of glucose, or to tolbutamide, which 5 
is an ATP-sensitive K+ (KATP) channel blocker (26). The electrophysiological experiments were 6 
undertaken at 1.5 mM [Ca2+]o, as described (25), and the effect of lowering the [Ca2+]o on β-cell 7 
electrical activity was evaluated at 0.75 mM [Ca2+]o, which is in keeping with the plasma calcium 8 
concentrations of CasrNuf/Nuf mice (15,16). Analysis of membrane potentials showed β-cells from 9 
Casr+/+ mice (i.e. WTs) to be hyperpolarised (-76 ± 2 mV) and electrically silent at 1 mM glucose 10 
concentrations (Figure 7A). In contrast, CasrNuf/Nuf β-cells were significantly depolarized (-63 ± 5 mV, 11 
p < 0.01) at 1 mM glucose, and >40% (4 out of 9) of cells were electrically active with low frequency 12 
action potential firing (Figure 7A). The depolarization and hyperactivity of CasrNuf/Nuf β-cells was 13 
rectified by lowering [Ca2+]o from 1.5 mM to 0.75 mM (Figure 7B-C). At stimulatory glucose 14 
concentrations (12 or 20 mM) or following application of tolbutamide, both Casr+/+ and CasrNuf/Nuf -15 
cells were depolarized and firing action potentials (Figure 7A-B), and the level of the depolarization 16 
was not altered in CasrNuf/Nuf -cells (Figure 7C). However, the peak of action potential evoked by 20 17 
mM glucose in CasrNuf/Nuf β-cells was significantly reduced compared to Casr+/+ β-cells (Figure 7D). 18 
The anti-peak potential and firing frequency were not affected by the expression of the Casr mutation 19 
or variation in [Ca2+]o (Figure 7E-F). Based on the observation that Casr
Nuf/Nuf β-cells were 20 
significantly depolarized at 1 mM glucose, we postulated that the CaSR may influence the KATP 21 
channel, which plays a central role in regulating the membrane potential of β-cells (1). We therefore 22 
measured resting conductance, which predominantly reflects KATP channel activity, of Casr
+/+ and 23 
CasrNuf/Nuf -cells in the presence of 1, 12 or 20 mM glucose, or with tolbutamide. These studies 24 
showed -cell resting conductance to be comparable between genotypes (Figure 8A-B). However, the 25 
holding current measured at – 70 mV in CasrNuf/Nuf -cells when KATP channel activity was suppressed 26 
by 20 mM glucose or tolbutamide was significantly greater than in Casr+/+ -cells (Figure 8C-D), and 27 
 17 
its contribution likely accounts for the more depolarized membrane potential and action potential 1 
firing in CasrNuf/Nuf -cells exposed to 1 mM glucose (Figure 7A). 2 
To determine whether Nuf mice may also have alterations in α-cell electrical activity, 3 
membrane potentials were recorded in intact islet α-cells, as described (26). In agreement with 4 
previous reports (37), Casr+/+ α-cells were shown to be electrically active at 1 mM glucose (Figure 5 
9A). The addition of 6 mM glucose led to a small but statistically significant (p < 0.01) depolarisation 6 
and reduction in action potential peak (Figure 9A). CasrNuf/Nuf α-cells were also electrically active at 1 7 
mM glucose (Figure 9B), but did not depolarise when glucose was increased to 6 mM (Figure 9B-C) 8 
and there was no change in the action potential peak (Figure 9B and 9D). The addition of tolbutamide 9 
led to membrane depolarization in both Casr+/+ and CasrNuf/Nuf α-cells (Figure 9A-B) but the 10 
magnitude of the depolarizing effect was reduced in CasrNuf/Nuf α-cells (Figure 9C). Tolbutamide also 11 
decreased the action potential peak of Casr+/+ α-cells, but had no significant effect on the action 12 
potential peak of CasrNuf/Nuf α-cells (Figure 9A-B and 9D). There were no significant differences in the 13 
action potential frequency between Casr+/+ and CasrNuf/Nuf α-cells and this was not affected by varying 14 
glucose or with the addition of tolbutamide (Figure 9E).  15 
 18 
Discussion 1 
 2 
Our studies have shown an in vivo role for the CaSR in glucose homeostasis, and in the regulation of 3 
pancreatic islet mass and islet hormone secretion. Thus, Nuf mice with a gain-of-function CaSR 4 
mutation exhibited impaired glucose tolerance, which was associated with reduced pancreatic islet 5 
mass and hypoinsulinemia, as well as a lack of glucose-mediated suppression of glucagon secretion. 6 
Moreover, these findings indicate that ADH-causing mutations of the CaSR, which lead to a gain-of 7 
function (14), may perturb systemic glucose homeostasis, and this contrasts with FHH-causing loss-of-8 
function CaSR mutations, which have been shown to not influence glucose tolerance or insulin 9 
secretion (13). Furthermore, these findings suggest that a common coding-region CaSR SNP 10 
(Ala986Ser), which was reported in association with raised plasma glucose concentrations in a patient-11 
based study (12), may have altered CaSR function in tissues involved in systemic glucose regulation. 12 
However, impaired glucose tolerance or diabetes has not been reported in ADH patients to-date, and 13 
detailed investigations of glucose homeostasis in humans are warranted.  14 
Although our studies showed CaSR activation to influence plasma glucose concentrations, we 15 
did not observe any effect of extracellular glucose on the acute signalling responses of WT or mutant 16 
Nuf CaSRs in vitro. Our findings are consistent with results obtained by other groups (personal 17 
communications from A. Conigrave and D. Ward), but contrast with a recent study, which showed that 18 
raising the glucose concentration from 3 to 5 mM increased the Ca2+i responses of stably expressing 19 
HEK293-CaSR cells in the presence of Ca2+o (30). This recent study, which showed glucose to act as a 20 
CaSR allosteric activator, measured Ca2+i responses in single cells using the fluo-8 calcium binding 21 
dye (30), whereas, our study measured Ca2+i responses in populations of HEK293-CaSR cells using the 22 
fluo-4 calcium binding dye; and these methodological differences may be contributors to the 23 
contrasting observations of these two studies. 24 
The CaSR is a therapeutic target for calcitropic diseases (14,38), and our studies involving the 25 
administration of ronacaleret, which is a calcilytic compound, to Nuf mice, showed that 26 
pharmacological modulation of the CaSR may also alter plasma glucose concentrations. Ronacaleret 27 
treatment rectified the hypocalcemia of heterozygous-affected (CasrNuf/+) mice and this was associated 28 
 19 
with an increase in plasma insulin concentrations. Thus, these findings suggest that ronacaleret 1 
rectified the impaired glucose tolerance and hypoinsulinemia of CasrNuf/+ mice by modulating their 2 
plasma calcium concentrations, and this is in keeping with our analysis of isolated Nuf mice islets, 3 
which demonstrated that Ca2+o is required for insulin release, and is also supported by a study showing 4 
that patients with chronic hypocalcemia have reduced glucose-stimulated insulin secretion (39). 5 
However, ronacaleret treatment also improved the glucose tolerance of homozygous-affected 6 
(CasrNuf/Nuf) mice without fully normalising their plasma calcium concentrations, or altering plasma 7 
insulin or glucagon concentrations. Thus, these studies involving CasrNuf/Nuf mice suggest that 8 
ronacaleret likely had additional effects on the glucose tolerance of Nuf mice, independently of 9 
altering plasma concentrations of calcium, insulin and glucagon. The CaSR is expressed in peripheral 10 
tissues such as skeletal muscle and adipose tissue (40,41), and it remains to be established whether 11 
ronacaleret treatment may potentially have sensitised these tissues to the actions of insulin, thereby 12 
improving glucose tolerance.  13 
Histological analysis revealed Nuf mice to have a significant reduction in mean islet area, and 14 
these findings may have contributed to their reduced plasma insulin concentrations and impaired 15 
glucose tolerance. Indeed, a decrease in pancreatic -cell mass is considered to be important in the 16 
pathogenesis of type 2 diabetes, as highlighted by a study of a mouse model with restricted -cell 17 
expansion, which showed that a 30% reduction in -cell mass is sufficient to result in impaired 18 
glucose tolerance (42). Our histological analyses also revealed individual CasrNuf/Nuf islets to have a 19 
significant reduction in the proportion of -cells compared to Casr+/+ islets. Thus, these findings 20 
indicate that the CaSR may influence pancreatic islet size and the cellular composition of individual 21 
islets, and suggest a role for this GPCR in the development and/or maintenance of -cell mass. In 22 
support of this, mouse model studies of the α-2A adrenergic receptor, which is highly expressed in -23 
cells, have shown GPCR signaling to play a critical role in modulating pancreatic islet mass by 24 
inhibiting -cell proliferation during the perinatal period (42). In keeping with this observation, CaSR 25 
activation was also associated with significantly reduced -cell proliferation in adult CasrNuf/Nuf islets, 26 
which may have contributed to the reduced size of Nuf mouse islets. However, -cell proliferation was 27 
measured using the Ki67 marker, which shows proliferation over a limited timeframe, and long-term 28 
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continuous labeling with the thymidine analog 5-bromo-2-deoxyuridine (BrdU) is required to provide 1 
a more accurate assessment of proliferation (43). Moreover, genes reported to be involved in the 2 
regulation of islet cell proliferation did not show altered expression in CasrNuf/Nuf islets. Thus, it is 3 
possible that the gain-of-function CaSR mutation harbored by Nuf mice may have exerted a greater 4 
influence on islet size during the perinatal and early postnatal periods, when the -cell population is 5 
undergoing a rapid expansion, and at this key developmental stage, alterations in cellular proliferation 6 
can substantially impact on adult -cell mass and insulin secretory capacity (42). Furthermore, the 7 
CaSR may have influenced -cell apoptosis, which has been shown to contribute to the reduced islet 8 
mass in humans with type 2 diabetes (44). 9 
Isolated Nuf mouse islets were shown to have alterations in -cell electrical activity, and 10 
CasrNuf/Nuf -cells were significantly depolarised and electrically active at low glucose concentrations. 11 
These findings suggest that the CaSR may influence the basal electrical activity of the β-cell, most 12 
likely by increasing background conductance (Figure 8). In support of this, lowering the concentration 13 
of Ca2+o, which represents the major physiological ligand of the CaSR (14), rectified the increased 14 
basal activity of CasrNuf/Nuf β-cells. Although the KATP channel plays an essential role in regulating the 15 
β-cell resting membrane potential (45), KATP channel conductance was not altered in Casr
Nuf/Nuf β-cells, 16 
and the higher background conductance was resistant to the effects of tolbutamide. Thus, the basal 17 
hyperactivity of CasrNuf/Nuf β-cells may have been mediated by a KATP channel-independent mechanism. 18 
A previous study has demonstrated that the transient receptor potential (TRP) M4 and TRPM5 ion 19 
channels regulate -cell membrane potential, and activation of these channels leads to increased β-cell 20 
electrical activity (25). As TRPM4 and TRPM5 channels have been shown to be activated by Gq/11-21 
mediated phosphoinositide signaling (25), it is possible that CaSR activation induced depolarisation 22 
and hyperactivity of -cells by enhancing the opening of these channels. However, due to a lack of 23 
selective channel blockers, it remains to be established whether CaSR may act via TRPM4 and 24 
TRPM5 in -cells. Interestingly, the increased electrical activity of CasrNuf/Nuf β-cells at 1 mM glucose 25 
was not associated with an increase in basal insulin secretion. The release of insulin has been shown to 26 
be mediated by a combination of triggering effects (mediated by KATP channel closure and initiation of 27 
action potential firing) and late amplifying effects (exerted at the level of insulin granule exocytosis) 28 
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(1). Thus, although CasrNuf/Nuf β-cells generated action potentials at low glucose, this may not 1 
necessarily have stimulated insulin secretion. Moreover, the CaSR did not influence the overall 2 
responses of β-cells to stimulatory glucose concentrations; however, a reduced spike height of the 3 
glucose-induced action potentials in CasrNuf/Nuf -cells was observed. The generation of action 4 
potentials in β-cells is mediated by Ca2+ influx through the L-type voltage-dependent Ca2+ channel 5 
(VDCC) (46), and our observation of altered action potential height provides support for an interaction 6 
between the CaSR and L-type VDCC, as has been previously reported (47).  7 
A key finding in this study was the presence of dysregulated glucagon secretion and altered α-8 
cell function in CasrNuf/Nuf mice. Glucagon plays a central role in systemic glucose homeostasis by 9 
stimulating hepatic glucose production, and over-secretion of glucagon contributes to the 10 
hyperglycemia in type 2 diabetes (48). The release of glucagon from α-cells is physiologically 11 
inhibited by elevations in glucose concentrations (26,48). However, high glucose concentrations failed 12 
to suppress glucagon secretion from CasrNuf/Nuf islets. We investigated whether alterations in the 13 
electrical activity of CasrNuf/Nuf α-cells may have impaired the suppression of glucagon secretion 14 
following exposure to high glucose. In WT α-cells, glucose regulates glucagon secretion via closure of 15 
the KATP channel, and the resulting membrane depolarization leads to reduced activation of P/Q-type 16 
VDCCs that mediate the Ca2+ entry responsible for hypoglycemia-induced glucagon secretion 17 
(26,37,48). However, in CasrNuf/Nuf α-cells, glucose did not induce membrane depolarization, and 18 
tolbutamide only caused a modest depolarization (~2mV), whereas this KATP channel blocker 19 
increased membrane potential by ~10 mV in Casr+/+ α-cells (Figure 9). Together, these data suggest 20 
that CaSR activation may have attenuated α-cell basal KATP channel activity, which impaired the 21 
membrane depolarizing effect of glucose and tolbutamide. Furthermore, CasrNuf/Nuf mice exhibited an 22 
increase in α-cell numbers within individual islets, enhanced α-cell proliferation rates, and 23 
significantly elevated islet glucagon content. These findings highlight a potential and novel role for the 24 
CaSR in promoting α-cell neogenesis, but it is also possible that the hypoinsulinemia of Nuf mice may 25 
have led to an expansion of α-cells, as has previously been reported in mice with streptozotocin-26 
induced insulin deficiency (49). 27 
 22 
In conclusion, we have demonstrated that Nuf mice with a germline gain-of-function CaSR 1 
mutation have impaired glucose tolerance, which can be ameliorated by calcilytic treatment. 2 
Moreover, our findings reveal a role for the CaSR in the regulation of pancreatic islet mass, and α- and 3 
-cell function. 4 
5 
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Figure legends 1 
 2 
Figure 1. Plasma glucose, insulin and glucagon concentrations during intraperitoneal glucose 3 
tolerance (IPGTT) testing. (A) Male and (B) female CasrNuf/+ (blue) and CasrNuf/Nuf mice (red) are 4 
significantly hyperglycemic compared to respective Casr+/+ mice (black) during a 2 hour IPGTT. (C) 5 
Male and (D) female CasrNuf/Nuf mice, and male CasrNuf/+ mice have significantly reduced plasma 6 
insulin concentrations compared to respective Casr+/+ mice during a 30 min IPGTT. (E) Male and (F) 7 
female CasrNuf/Nuf mice show significant elevations in plasma glucagon concentrations compared to 8 
respective Casr+/+ mice during a 2 hour IPGTT. Results are expressed as mean ± SEM. *p < 0.05, **p 9 
< 0.01, ***p < 0.001 compared to Casr+/+ mice at respective time-points.  10 
 11 
Figure 2. Effect of ronacaleret on the CaSR gain-of-function and hypocalcemia of Nuf mice. (A) 12 
Fluorescence microscopy of HEK293 cells transiently transfected with WT Leu723 or mutant (m) 13 
Gln723 CASR-pEGFP-N1 constructs. GFP expression in these cells indicates successful transfection 14 
and expression by these constructs. Bar indicates 10 μm. (B) Effect of ronacaleret treatment on the 15 
intracellular calcium responses of the Gln723 CaSR mutant. The Gln723 CaSR mutant led to a 16 
leftward shift in the concentration-response curve (solid red line) compared to the WT (Leu723) CaSR 17 
(solid black line). The addition of ronacaleret (Rona) at 20 nM and 40 nM concentrations rectified the 18 
leftward shift of the Gln723 CaSR mutant (red dotted line and red dashed line, respectively). The 19 
zoomed-in image shows the concentration-response curves at the EC50 values of the WT and mutant 20 
CaSRs. (C) Effect of 20 nM and 40 nM ronacaleret on the EC50 values of the Gln723 CaSR mutant. 21 
(D) Male and (E) female CasrNuf/+ and CasrNuf/Nuf mice were significantly hypocalcemic compared to 22 
respective Casr+/+ mice. Treatment with 90 mg/kg ronacaleret significantly increased plasma calcium 23 
concentrations in Casr+/+, CasrNuf/+ and CasrNuf/Nuf mice compared to respective mice treated with the 24 
drug vehicle only. Ronacaleret treatment normalised the plasma calcium concentrations of CasrNuf/+ 25 
mice. However, the plasma calcium concentrations of treated CasrNuf/Nuf mice remained significantly 26 
reduced compared to untreated Casr+/+ mice. Mean ± SEM values are indicated by solid bars. NS, 27 
non-significant, *p < 0.05, **p < 0.01, ***p < 0.001. 28 
 27 
Figure 3. Effect of ronacaleret on the plasma glucose, insulin and glucagon concentrations of 1 
male mice during intraperitoneal glucose tolerance testing (IPGTT). Ronacaleret administration 2 
had no effect on the plasma glucose concentrations of (A) Casr+/+ mice (black dashed line), but 3 
significantly lowered plasma glucose in (B) CasrNuf/+ (blue dashed line) and (C) CasrNuf/Nuf mice (red 4 
dashed line) compared to respective control mice treated with the drug vehicle only (represented by 5 
solid lines), so that the glucose concentrations were not significantly different from Casr+/+ mice. 6 
Ronacaleret had no effect on the plasma insulin concentrations of (D) Casr+/+ mice, but significantly 7 
increased plasma insulin in (E) CasrNuf/+ mice compared to controls, so that the insulin concentrations 8 
were not significantly different from Casr+/+ mice. Ronacaleret treatment did not alter plasma insulin 9 
concentrations in (F) CasrNuf/Nuf mice. Ronacaleret had no significant effect on the plasma glucagon 10 
concentrations of (G) Casr+/+ mice, (H) CasrNuf/+ mice, or (I) CasrNuf/Nuf mice compared to respective 11 
control mice. Results are expressed as mean ± SEM. *p < 0.05, **p < 0.01 compared to control mice. 12 
 13 
Figure 4. Effect of ronacaleret on the plasma glucose, insulin and glucagon concentrations of 14 
female mice during intraperitoneal glucose tolerance testing (IPGTT). Ronacaleret administration 15 
had no effect on the plasma glucose concentrations of (A) Casr+/+ mice (black dashed line), but 16 
significantly lowered plasma glucose in (B) CasrNuf/+ (blue dashed line) and (C) CasrNuf/Nuf mice (red 17 
dashed line) compared to respective control mice treated with the drug vehicle only (represented by 18 
solid lines), so that the glucose concentrations were not significantly different from Casr+/+ mice. 19 
Ronacaleret had no effect on the plasma insulin concentrations of (D) Casr+/+ mice, but significantly 20 
increased plasma insulin in (E) CasrNuf/+ mice compared to controls, so that the insulin concentrations 21 
were not significantly different from Casr+/+ mice. Ronacaleret treatment did not alter plasma insulin 22 
concentrations in (F) CasrNuf/Nuf mice. Ronacaleret had no significant effect on the plasma glucagon 23 
concentrations of (G) Casr+/+ mice, (H) CasrNuf/+ mice, or (I) CasrNuf/Nuf mice compared to respective 24 
control mice. Results are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared to 25 
control mice.  26 
 27 
 28 
Figure 5. Histological analysis of Nuf mice pancreatic islets. (A) Representative H&E stained 1 
pancreatic sections from Casr+/+, CasrNuf/+ and CasrNuf/Nuf mice. Bars indicate 200μm. (B) Islet area and 2 
(C) number are significantly reduced in CasrNuf/+ and CasrNuf/Nuf mice compared to Casr+/+ mice. (D) 3 
Islet size is significantly reduced in CasrNuf/Nuf mice compared to Casr+/+ mice. (E) Representative 4 
pancreatic islets from Casr+/+, CasrNuf/+ and CasrNuf/Nuf mice immunostained for glucagon (red), insulin 5 
(white) and DAPI (blue). Bars indicate 50μm. (F) CasrNuf/Nuf mice have significantly reduced β-cell 6 
numbers and (G) significantly increased α-cell numbers compared to Casr+/+ mice. (H) β-cell 7 
proliferation in representative islets from Casr+/+, CasrNuf/+ and CasrNuf/Nuf mice immunostained for 8 
insulin (white), DAPI (blue) and KI-67 (red). KI-67 positive cells are also indicated by yellow arrows. 9 
Bars indicate 50μm. (I) CasrNuf/Nuf mice have significantly reduced proliferation of β-cells and (J) 10 
significantly increased proliferation of α-cells compared to respective Casr+/+ mice. Results are 11 
expressed as mean ± SEM. *p < 0.05, **p < 0.01 compared to Casr+/+ mice. 12 
 13 
Figure 6. Insulin and glucagon secretion from isolated Nuf mice pancreatic islets. (A) The total 14 
insulin content of CasrNuf/Nuf islets was not altered compared to Casr+/+ islets. (B) Casr+/+ and 15 
CasrNuf/Nuf islets were incubated in 1.6 mM [Ca2+]o and exposed to varying glucose concentrations (1 16 
mM, 6 mM or 20 mM). Casr+/+ and CasrNuf/Nuf islets showed significantly increased insulin secretion 17 
following stimulation with 20 mM glucose. No significant differences in the maximal insulin secretory 18 
responses were observed between Casr+/+ and CasrNuf/Nuf islets. (C) The total glucagon content of 19 
CasrNuf/Nuf islets was significantly increased compared to Casr+/+ islets. (D) Casr+/+ and CasrNuf/Nuf 20 
islets were incubated in 1.6 mM [Ca2+]o and exposed to 1 mM and 6 mM glucose concentrations. 21 
Casr+/+ islets showed a significant reduction in glucagon secretion following stimulation with 6 mM 22 
glucose. In contrast, glucagon secretion from CasrNuf/Nuf islets failed to suppress following glucose 23 
stimulation, and CasrNuf/Nuf islets had significantly increased glucagon secretion compared to Casr+/+ 24 
islets at 6 mM glucose. (E) The effect of extracellular calcium (Ca2+o) on insulin secretion was 25 
assessed by incubating Casr+/+ and CasrNuf/Nuf islets with varying Ca2+o concentrations (0.8 mM or 1.6 26 
mM) and exposing them to low (1 mM) or high (20 mM) glucose. Exposure to low (0.8 mM) Ca2+o 27 
suppressed insulin secretion from Casr+/+ and CasrNuf/Nuf islets at 20 mM glucose. (F) Exposure to low 28 
 29 
(0.8 mM) Ca2+o increased glucagon secretion from Casr
+/+ islets at 20 mM glucose, but had no effect 1 
on glucagon secretion from CasrNuf/Nuf islets. Islet insulin and glucagon in A-D was measured by 2 
radioimmunoassay, and by duplex Rat/Mouse ELISA (Meso Scale Discovery) in E-F. The sample size 3 
(N) represents batches of size-matched islets, which were pooled from 3-6 Casr+/+ mice and 6 4 
CasrNuf/Nuf mice. Mean ± SEM values for the respective groups are indicated by solid bars. NS, non-5 
significant, *p < 0.05, **p <0.01, ***p < 0.001.  6 
 7 
Figure 7. Effect of glucose stimulation on the electrical activity of Nuf mice β-cells. (A) 8 
Representative membrane potential recording of β-cells from intact Casr+/+ and CasrNuf/Nuf after islets 9 
had been incubated in 1.5 mM [Ca2+]o and following stimulation with 1 mM (1G), 12 mM (12G) and 10 
20 mM (20G) glucose concentrations or with tolbutamide (Tolb). (B) Representative membrane 11 
potential recording of β-cells from intact Casr+/+ and CasrNuf/Nuf islets in the presence of 0.75 mM 12 
Ca2+o concentrations and following stimulation with 1, 12, or 20 mM glucose concentrations or with 13 
tolbutamide. (C) Basal membrane potential, (D) action potential peak, (E) anti-peak potential, and (F) 14 
frequency of action potential firing from β-cells was assessed in intact Casr+/+ (open bars) and 15 
CasrNuf/Nuf islets (black bars) in the presence of 1.5 or 0.75 mM Ca2+o concentrations and following 16 
stimulation with glucose or tolbutamide. The sample size (N) represents individual β-cell recordings 17 
obtained from intact islets of 6 Casr+/+ mice and 4 CasrNuf/Nuf mice. Results are expressed as mean ± 18 
SEM. *p <0.05, **p <0.01 compared to Casr+/+ mice at respective glucose and Ca2+o concentrations. 19 
 20 
Figure 8. KATP channel conductance of Nuf mice β-cells. (A) Representative recording of β-cell 21 
KATP channel conductance from intact Casr
+/+ and CasrNuf/Nuf islets after islets had been incubated in 22 
1.5 mM [Ca2+]o and following stimulation with 1 mM (1G), 12 mM (12G) and 20 mM (20G) glucose 23 
concentrations or with tolbutamide (Tolb). (B) Analysis of KATP channel conductance from β-cells 24 
within intact Casr+/+ (open bars) and CasrNuf/Nuf islets (black bars) following stimulation with glucose 25 
or tolbutamide. (C) Representative traces of β-cell background current measurement following glucose 26 
stimulation or treatment with tolbutamide. (D) Analysis of holding current from β-cells within intact 27 
Casr+/+ (open bars) and CasrNuf/Nuf islets (black bars) following stimulation with glucose or 28 
 30 
tolbutamide. The sample size (N) represents individual β-cell recordings obtained from intact islets of 1 
5 Casr+/+ mice and 5 CasrNuf/Nuf mice. Results are expressed as mean ± SEM. *p < 0.05, **p < 0.01 2 
compared to Casr+/+ mice at respective glucose and tolbutamide concentrations. 3 
 4 
Figure 9. Effect of glucose stimulation on the electrical activity of Nuf mice α-cells. Representative 5 
membrane potential recording of α-cells from (A) intact Casr+/+ and (B) CasrNuf/Nuf islets after islets 6 
had been incubated in 1.5 mM [Ca2+]o and following stimulation with 1 mM (1G) and 6 mM (6G) 7 
glucose concentrations or with tolbutamide (Tolb). (C) Anti-peak potential, (D) action potential peak, 8 
and (E) frequency of action potential firing was assessed in α-cells within intact Casr+/+ (open bars) 9 
and CasrNuf/Nuf islets (black bars) following stimulation with glucose or tolbutamide. The sample size 10 
(N) represents individual α-cell recordings obtained from intact islets of 5 Casr+/+ mice and 7 11 
CasrNuf/Nuf mice. Results are expressed as mean ± SEM. *p <0.05, **p <0.01 compared to respective α-12 
cells at 1 mM glucose. 13 
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Peptide/protein target Antigen sequence (if known) Name of Antibody
Manufacturer, catalog #, 
and/or name of individual 
providing the antibody
Species raised in; monoclonal or 
polyclonal
Dilution used
Primary antibodies
Insulin Anti-insulin abcam, ab7842 guinea pig; polyclonal 0.005
Glucagon Anti-glucagon abcam, ab92517 rabbit; monoclonal 0.005
Ki67 Anti-Ki67 abcam, ab15580 rabbit; polyclonal 0.002
Secondary antibodies
Anti-Guinea pig IgG (H+L) Cy™2 AffiniPure Donkey Anti-Guinea Pig IgG (H+L)Jackson, 706-225-148 donkey; polyclonal 0.01
Anti-Rabbit IgG (H+L) Cy™3 AffiniPure Donkey Anti-Rabbit IgG (H+L) Jackson, 711-165-152 donkey; polyclonal 0.002
Antibody Table
